A Phase 2 interventional study of Ibrutinib and Venetoclax in Mantle Cell Lymphoma (MCL), sponsored by AbbVie. Completed at 12 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing ibrutinib in Lymphoma, Mantle-Cell — 2 open to participants now, 16 under way, 2 of them phase 3. ibrutinib · Lymphoma, Mantle-Cell.
Among the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell, this one is the 36th largest by enrollment, is one of 4 that started in 2020, is one of 21 in phase 2, and was the 39th registered.
1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 154 are open to participants now.
Browse Lymphoma, Mantle-Cell studies →2 of the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell are open now, in 6 countries. Recruiting first, the newest first:
OHSU Knight Cancer Institute · Sites in United States
Ages 18+
Prof. Dr. M. Dreyling (co-chairman) · Sites in Denmark, Germany, Italy and 2 more countries
Ages 18–65
By country, each count listing its studies:
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 26 · Phase 3 6 · Phase 4 1
First in 2009; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.
Median enrollment 39 across the 45 interventional studies. Of the 24 that completed or were terminated, 12 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 45 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
10 studies in Lymphoma, Mantle-Cell by AbbVie: none open now, 2 under way, none of them phase 3. Of 8 finished, 5 (63%) have results posted.
Among the 10 studies in Lymphoma, Mantle-Cell by AbbVie, this one is the 9th largest by enrollment, is the only one that started in 2020, is one of 3 in phase 2, and was the 7th registered.
AbbVie’s Lymphoma, Mantle-Cell studies by the year they started, since 2006.
6 of the studies testing ibrutinib in Lymphoma, Mantle-Cell that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT03710772M.D. Anderson Cancer CenterIbrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | 2027-03-22 |
| NCT03153202Joshua BrodyStudy to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | 2027-04 |
| NCT02427620M.D. Anderson Cancer CenterIbrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell, from their registry updates:
Among AbbVie’s 10 in Lymphoma, Mantle-Cell:
This tab as a report to print or save as PDF → With an account.
Mantle Cell Lymphoma (MCL) is a form of Non-Hodgkin Lymphoma (NHL - cancer of the lymphatic system in blood) where cells from outer edge of the lymph nodes, called mantle zone become cancerous. In Japan, MCL accounts for about 3% of all NHL cases. Symptoms of MCL may include enlarged lymph nodes, stomach pain, fever, night sweats, and weight loss. Currently, MCL is not curable with standard therapies. The purpose of this study is to evaluate the safety, efficacy, and effect of venetoclax in combination with ibrutinib on best overall response of complete response in participants with relapsed (return of disease) or refractory (not responding to treatment) (R/R) MCL.
Venetoclax is an investigational drug being developed for the treatment of MCL. Ibrutinib is a drug approved for the treatment of MCL. Participants will receive venetoclax (increasing doses) and ibrutinib (fixed dose) for approximately 104 weeks, followed by ibrutinib alone. Adult participants with R/R MCL will be enrolled. Around 12 participants will be enrolled in Japan.
Participants will receive oral venetoclax tablet and oral ibrutinib capsule for 104 weeks. After 104 weeks, participants will receive ibrutinib once daily until their disease progresses, or they cannot tolerate the medication, or until they do not want to participate in the study.
There may be a higher treatment burden for participants in this study compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, bone marrow biopsies, checking for side effects, and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of other , except:
Treatment with any of the following within 7 days prior to the first dose of study drug:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Ibrutinib Dose A + Venetoclax in various doses until a target dose is reached, for up to 104 weeks, followed by Ibrutinib monotherapy.
Drug: Ibrutinib · Drug: Venetoclax
Capsule; Oral
Also known as: Imbruvica
Tablet; Oral
Also known as: ABT-199, Venclexta, GDC-0199, Venclyxto
Percentage of Participants Achieving Best Overall Response of Complete Response (CR), as Assessed by the Independent Review Committee (IRC)
Complete response rate (CRR), defined as the percentage of participants achieving a best overall response of complete response (CR) per the Revised Criteria for Response Assessment for Malignant Lymphoma following the Lugano classification (Cheson 2014), assessed by an Independent Review Committee (IRC).
Time frame: Week 13
Percentage of Participants Achieving Best Overall Response of CR or PR, as Assessed by the IRC
Overall Response Rate (ORR), defined as the percentage of participants with a best overall response of CR or PR, per the Revised Criteria for Response Assessment for Malignant Lymphoma, assessed by an Independent Review Committee (IRC).
Time frame: Median follow-up time of 48 months (range: 2.3 to 50.7)
Percentage of Participants Achieving Best Overall Response of CR as Assessed by the Investigator
Best overall response of CR is defined as the percentage of participants achieving a best overall response of CR for the venetoclax and ibrutinib combination, as assessed by the investigator per the Revised Criteria for Response Assessment for Malignant Lymphoma .
Time frame: Median follow-up time of 48 months (range: 2.3 to 50.7)
Percentage of Participants Achieving Best Overall Response of CR or PR, as Assessed by the Investigator
Best overall response of CR or PR will be evaluated using ORR. The ORR is defined as the percentage of participants with a best overall response of CR or PR, according to the Revised Criteria for Response Assessment for Malignant Lymphoma, as assessed by the investigator.
Time frame: Median follow-up time of 48 months (range: 2.3 to 50.7)
Duration of Response (DOR) for Participants Who Achieved a Best Overall Response of CR or PR, as Assessed by the Investigator
DOR is defined as the time from the first occurrence of response (CR or PR) to disease progression or death, whichever occurs first, according to the Revised Criteria for Response Assessment for Malignant Lymphoma, as assessed by the investigator.
Time frame: Median follow-up time of 48 months (range: 2.3 to 50.7)
DOR for Participants Who Achieved a Best Overall Response of CR or PR, as Assessed by the IRC
DOR is defined as the time from the first occurrence of response (CR or PR) to disease progression or death, whichever occurs first, according to the Revised Criteria for Response Assessment for Malignant Lymphoma, as assessed by the IRC.
Time frame: Median follow-up time of 48 months (range: 2.3 to 50.7)
Undetectable Minimal Residual Disease (uMRD) in Peripheral Blood in Participants Who Achieve a Best Overall Response of CR as Assessed by the Investigator and the IRC
MRD rate is defined as the percentage of participants with uMRD who achieve a best overall response of CR, according to the Revised Criteria for Response Assessment for Malignant Lymphoma, as assessed by the investigator.
Time frame: Median follow-up time of 48 months (range: 2.3 to 50.7)
uMRD in Bone Marrow Participants Who Achieve a Best Overall Response of CR as Assessed by the Investigator and the IRC.
MRD rate is defined as the percentage of participants with uMRD who achieve a best overall response of CR, according to the Revised Criteria for Response Assessment for Malignant Lymphoma, as assessed by investigator and the IRC.
Time frame: Median follow-up time of 48 months (range: 2.3 to 50.7)
Progression-Free Survival (PFS)
PFS is defined as the time from the date of the first dose of study drug (venetoclax or ibrutinib) to the date of investigator-assessed disease progression, using the Revised Response Criteria for Response Assessment for Malignant Lymphoma, or death from any cause, whichever occurs first.
Time frame: Median follow-up time of 48 months (range: 2.3 to 50.7)
Overall Survival (OS)
OS is defined as the time from the date of the first dose of the study drug (venetoclax or ibrutinib) to death from any cause.
Time frame: Median follow-up time of 48 months (range: 2.3 to 50.7)
A total of 13 participants were enrolled across 8 sites in Japan. The study was not considered terminated because, after venetoclax plus ibrutinib combination therapy was approved in Japan for relapsed/refractory mantle cell lymphoma, the remaining participants transitioned to commercially available drug supply or other available treatment options. As specified in the protocol, the study was therefore considered discontinued rather than terminated.
| Milestone | Ibrutinib + Venetoclax |
|---|---|
| Started | 13 |
| Completed | 0 |
| Not completed | 13 |
| Withdrew: Death | 5 |
| Withdrew: Discontinued study - study terminated by sponsor | 8 |
Complete response rate (CRR), defined as the percentage of participants achieving a best overall response of complete response (CR) per the Revised Criteria for Response Assessment for Malignant Lymphoma following the Lugano classification (Cheson 2014), assessed by an Independent Review Committee (IRC).
| percentage of participants | Ibrutinib + Venetoclax |
|---|---|
| Percentage of Participants Achieving Best Overall Response of Complete Response (CR), as Assessed by the Independent Review Committee (IRC) | 83.3 (51.6 to 97.9) |
Overall Response Rate (ORR), defined as the percentage of participants with a best overall response of CR or PR, per the Revised Criteria for Response Assessment for Malignant Lymphoma, assessed by an Independent Review Committee (IRC).
| percentage of participants | Ibrutinib + Venetoclax |
|---|---|
| Percentage of Participants Achieving Best Overall Response of CR or PR, as Assessed by the IRC | 83.3 (51.6 to 97.9) |
Best overall response of CR is defined as the percentage of participants achieving a best overall response of CR for the venetoclax and ibrutinib combination, as assessed by the investigator per the Revised Criteria for Response Assessment for Malignant Lymphoma .
| percentage of participants | Ibrutinib + Venetoclax |
|---|---|
| Percentage of Participants Achieving Best Overall Response of CR as Assessed by the Investigator | 76.9 (46.2 to 95.0) |
Best overall response of CR or PR will be evaluated using ORR. The ORR is defined as the percentage of participants with a best overall response of CR or PR, according to the Revised Criteria for Response Assessment for Malignant Lymphoma, as assessed by the investigator.
| percentage of participants | Ibrutinib + Venetoclax |
|---|---|
| Percentage of Participants Achieving Best Overall Response of CR or PR, as Assessed by the Investigator | 76.9 (46.2 to 95.0) |
DOR is defined as the time from the first occurrence of response (CR or PR) to disease progression or death, whichever occurs first, according to the Revised Criteria for Response Assessment for Malignant Lymphoma, as assessed by the investigator.
| months | Ibrutinib + Venetoclax |
|---|---|
| Duration of Response (DOR) for Participants Who Achieved a Best Overall Response of CR or PR, as Assessed by the Investigator | NA (18.5 to NA) |
DOR is defined as the time from the first occurrence of response (CR or PR) to disease progression or death, whichever occurs first, according to the Revised Criteria for Response Assessment for Malignant Lymphoma, as assessed by the IRC.
| months | Ibrutinib + Venetoclax |
|---|---|
| DOR for Participants Who Achieved a Best Overall Response of CR or PR, as Assessed by the IRC | 45.2 (45.0 to NA) |
MRD rate is defined as the percentage of participants with uMRD who achieve a best overall response of CR, according to the Revised Criteria for Response Assessment for Malignant Lymphoma, as assessed by the investigator.
| percentage of participants | Ibrutinib + Venetoclax |
|---|---|
| Peripheral Blood (Per Investigator) | 100 (54.1 to 100) |
| Peripheral Blood (Per IRC) | 100 (54.1 to 100) |
MRD rate is defined as the percentage of participants with uMRD who achieve a best overall response of CR, according to the Revised Criteria for Response Assessment for Malignant Lymphoma, as assessed by investigator and the IRC.
| percentage of participants | Ibrutinib + Venetoclax |
|---|---|
| Bone Marrow (Per Investigator) | 100 (15.8 to 100) |
| Bone Marrow (Per IRC) | 100 (15.8 to 100) |
PFS is defined as the time from the date of the first dose of study drug (venetoclax or ibrutinib) to the date of investigator-assessed disease progression, using the Revised Response Criteria for Response Assessment for Malignant Lymphoma, or death from any cause, whichever occurs first.
| months | Ibrutinib + Venetoclax |
|---|---|
| Progression-Free Survival (PFS) | 43.4 (22.6 to NA) |
OS is defined as the time from the date of the first dose of the study drug (venetoclax or ibrutinib) to death from any cause.
| months | Ibrutinib + Venetoclax |
|---|---|
| Overall Survival (OS) | 48.2 (24.5 to NA) |
Collected over All-cause mortality and adverse event tables include events reported from enrollment to the end of the study. The median time participants were followed was 209 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ibrutinib + Venetoclax | 5/13 (38.5%) | 7/13 (53.8%) | 13/13 (100%) |
| Event | Ibrutinib + Venetoclax |
|---|---|
| PYREXIAGeneral disorders | 2/13 |
| COVID-19 PNEUMONIAInfections and infestations | 2/13 |
| NEUTROPENIABlood and lymphatic system disorders | 1/13 |
| GLAUCOMAEye disorders | 1/13 |
| HAEMORRHOIDSGastrointestinal disorders | 1/13 |
| LOWER GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders | 1/13 |
| PANCREATITISGastrointestinal disorders | 1/13 |
| BILE DUCT STENOSISHepatobiliary disorders | 1/13 |
| COVID-19Infections and infestations | 1/13 |
| INTERVERTEBRAL DISCITISInfections and infestations | 1/13 |
| Event | Ibrutinib + Venetoclax |
|---|---|
| DIARRHOEAGastrointestinal disorders | 7/13 |
| LEUKOPENIABlood and lymphatic system disorders | 5/13 |
| NEUTROPENIABlood and lymphatic system disorders | 5/13 |
| CONSTIPATIONGastrointestinal disorders | 5/13 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 4/13 |
| ATRIAL FIBRILLATIONCardiac disorders | 4/13 |
| PYREXIAGeneral disorders | 4/13 |
| SKIN INFECTIONInfections and infestations | 4/13 |
| ANAEMIABlood and lymphatic system disorders | 3/13 |
| NAUSEAGastrointestinal disorders | 3/13 |
Full Analysis Set (N=13)
| Age, Categorical(Participants) | Ibrutinib + Venetoclax |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 2 |
| >=65 years | 11 |
| Age, Continuous(Years) | Ibrutinib + Venetoclax |
|---|---|
| Mean | 69.8 ± 5.97 |
| Sex: Female, Male(Participants) | Ibrutinib + Venetoclax |
|---|---|
| Female | 3 |
| Male | 10 |
| Ethnicity (NIH/OMB)(Participants) | Ibrutinib + Venetoclax |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 13 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Ibrutinib + Venetoclax |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 13 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Ibrutinib + Venetoclax |
|---|---|
| Japan | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Sep 2020 to primary completion in Feb 2022, 16 months.
Results were first posted in Jan 2025, 2 years 11 months after primary completion. A results delay was requested in Dec 2022.
Of 30 industry-sponsored phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's 16 months is below that.
Counting every sponsor, half of 183 studies reached it within 63 months; a quarter within 38 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ibrutinib · Venetoclax